Search results
Order by most recent / most popular / relevance
Results: 1-10 of 197
Teva Canada Innovation v. Attorney General of Canada
- Borden Ladner Gervais LLP
- -
- Canada
- -
- May 8 2013
The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an
Intellectual property weekly abstracts bulletin
- Borden Ladner Gervais LLP
- -
- Canada
- -
- April 1 2013
The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the
NOC proceedings
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 25 2013
The Federal Court found Teva’s allegations of invalidity were not justified for Novartis’ narrow compound patent, while the allegations against
Decisions in leave to appeal to the Supreme Court
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 18 2013
The Supreme Court is releasing their judgment for two leave decisions this Thursday. The first, Gilead Science Canada Inc. v. Minister of Health
Patent found valid and infringed - accounting of profits awarded
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 18 2013
Apotex sued for impeachment of Lundbeck’s patent. Lundbeck counterclaimed for infringement. The Court held that the patent was valid and infringed
Motion to strike pleading mostly denied, but granted in part
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 27 2013
The Defendants brought a motion striking portions of the Statement of Claim under three different headings. Furthermore, particulars were sought. The
Other industry news
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 27 2013
Health Canada has released a Draft (Step 2) International Conference on Harmonisation of Technical Requirements for the Registration of
Compound patent found valid in face of allegations of lack of utilitysound prediction and insufficiency
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 27 2013
Apotex and Novopharm started actions to impeach Novartis’ patent covering the compound imatinib, sold under the brand name GLEEVEC. They then sent
NOC proceeding dismissed on the basis of overbreadth and a lack of sound prediction
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 13 2013
In this case, one claim of a patent was at issue in the proceeding. The claim related to the use of pregabalin or its racemate to treat pain. The
Application to amend inventorship allowed
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 6 2013
By this application, Sega sought an Order amending the named inventors of a patent. The application was uncontested by the respondent who did not file
Current Search
- Workarea - Patents
- Author - Beverley Moore